96 related articles for article (PubMed ID: 9431413)
1. Antibiotic therapy for foot infections in diabetics.
Hu XH; Markson LE; Abbott TA; Dasbach EJ; Berger ML
Clin Infect Dis; 1997 Dec; 25(6):1488-90. PubMed ID: 9431413
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
McKinnon PS; Paladino JA; Grayson ML; Gibbons GW; Karchmer AW
Clin Infect Dis; 1997 Jan; 24(1):57-63. PubMed ID: 8994756
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam.
Jellison TK; Mckinnon PS; Rybak MJ
Pharmacotherapy; 2001 Feb; 21(2):142-8. PubMed ID: 11213849
[TBL] [Abstract][Full Text] [Related]
4. Management and prevention of diabetic foot ulcers and infections: a health economic review.
Chow I; Lemos EV; Einarson TR
Pharmacoeconomics; 2008; 26(12):1019-35. PubMed ID: 19014203
[TBL] [Abstract][Full Text] [Related]
5. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
Grayson ML; Gibbons GW; Habershaw GM; Freeman DV; Pomposelli FB; Rosenblum BI; Levin E; Karchmer AW
Clin Infect Dis; 1994 May; 18(5):683-93. PubMed ID: 8075257
[TBL] [Abstract][Full Text] [Related]
6. [Comparative study of the cost-effectiveness of initial therapy with imipenem/cilastatin in secondary peritonitis].
Rodloff AC; Kujath P; Lünstedt B; Gaus W
Chirurg; 1998 Oct; 69(10):1093-100; discussion 1100. PubMed ID: 9833192
[TBL] [Abstract][Full Text] [Related]
7. [Peritonitis: dual treatment strategy of operation and antibiotics].
Chirurg; 1997 Aug; 68(8 Suppl):Suppl 1-4. PubMed ID: 9378001
[No Abstract] [Full Text] [Related]
8. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.
Wood GC; Hanes SD; Croce MA; Fabian TC; Boucher BA
Clin Infect Dis; 2002 Jun; 34(11):1425-30. PubMed ID: 12015687
[TBL] [Abstract][Full Text] [Related]
9. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
Dietrich ES; Schubert B; Ebner W; Daschner F
Pharmacoeconomics; 2001 Jan; 19(1):79-94. PubMed ID: 11252548
[TBL] [Abstract][Full Text] [Related]
10. A comparison of clinical and microbiological efficacy of antibiotic regimens against Acinetobacter baumannii.
Ackerman BH; Haith LR; Patton ML; Guilday RE; Reigart CL; Stair-Buchmann M
J Burn Care Res; 2013; 34(4):403-12. PubMed ID: 23237825
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study].
Rodloff AC; Laubenthal HJ; Bastian A; Bestehorn K; Büchele G; Gaus W
Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Apr; 31(3):172-80. PubMed ID: 8672620
[TBL] [Abstract][Full Text] [Related]
12. [Selective intraarterial application of Thienam and Vasoprostan in the treatment of purulent foot diseases in patients with diabetes mellitus].
Antsypovich EA; Molchanov VF; Kadyshev IuG; Brusnitsyna MA
Klin Khir; 1998; (8):53. PubMed ID: 9866335
[No Abstract] [Full Text] [Related]
13. Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin+aminoglycoside combination therapy for treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infections.
Kreter B
Clin Ther; 1992; 14(1):110-21. PubMed ID: 1576620
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany.
Dietrich ES; Patz E; Frank U; Daschner FD
Infection; 1999; 27(1):23-7. PubMed ID: 10027102
[TBL] [Abstract][Full Text] [Related]
15. Ampicillin-sulbactam versus cefoxitin for prophylaxis in high-risk patients undergoing abdominal surgery.
Paladino JA; Rainstein MA; Serrianne DJ; Przylucki JE; Welage LS; Collura ML; Schentag JJ
Pharmacotherapy; 1994; 14(6):734-9. PubMed ID: 7885978
[TBL] [Abstract][Full Text] [Related]
16. [Evidence-based medicine, health costs and treatment of intra-abdominal infection].
Badía X; Brosa M; Tellado JM
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():86-94. PubMed ID: 10605193
[TBL] [Abstract][Full Text] [Related]
17. [Contribution of imipenem-cilastatin in the treatment of peritonitis: a comparative economical analysis in the case of France].
Fichaux A; Akli J
J Chir (Paris); 1993 Oct; 130(10):441. PubMed ID: 8276916
[No Abstract] [Full Text] [Related]
18. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infection.
Barie PS; Rotstein OD; Dellinger EP; Grasela TH; Walawander CA
Surg Infect (Larchmt); 2004; 5(3):269-80. PubMed ID: 15684798
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.
Walters DJ; Solomkin JS; Paladino JA
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):551-61. PubMed ID: 10662480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
